Treatment
Orelabrutinib clinical trials
We’re tracking 51 recruiting studies that include Orelabrutinib, each written for real people, not researchers, below.
Recruiting studies
- NCT04989621RecruitingPhase 2
Orelabrutinib plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether orelabrutinib combined with rituximab, followed by orelabrutinib alone for a while, can control follicular lymphoma that has come back or did not respond. It may help shrink tumors and keep the disease from worsening after initial response.
Guangzhou, GuangdongAges 18 years+ - NCT05688696RecruitingPhase 2
Testing a drug called orelabrutinib for lupus symptoms in adults
This Phase 2 trial studies whether orelabrutinib can improve systemic lupus erythematosus (SLE) and check its safety. It may help people with active lupus who are already on stable lupus medicines.
Bengbu, AnhuiAges 18–75 - NCT07453368RecruitingPhase 2
Orelabrutinib for relapsed or hard-to-treat AIHA
This trial tests a targeted pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that has come back or not responded to standard treatments. It may help control your immune system's attack on your red blood cells.
Beijing, Beijing MunicipalityAges 18–85 - NCT06363994RecruitingPhase 3
Study of orelabrutinib plus BR for untreated mantle cell lymphoma
This trial tests a new combination of drugs (orelabrutinib plus BR) compared to BR alone for people with newly diagnosed mantle cell lymphoma who have not had treatment before. It may be an option if you are older or not able to have a stem cell transplant.
BeijingAges 60 years+ - NCT06504940RecruitingPhase 2
Study of orelabrutinib plus BR or G for untreated marginal zone lymphoma
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
Hangzhou, ZhejiangAges 18 years+ - NCT06793189RecruitingPhase 2
Risk-Adapted Targeted Therapy for Untreated MZL
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
Shanghai, ChinaAges 18 years+ - NCT07199296RecruitingPhase 2
Study of orelabrutinib and rituximab with optional stem cell transplant for mantle cell lymphoma
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
ShanghaiAges 14 years+ - NCT07067463RecruitingPhase 3
Testing orelabrutinib for primary progressive MS
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Pheonix, ArizonaAges 18–60 - NCT07299019RecruitingPhase 3
Study of orelabrutinib for secondary progressive MS
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
Phoenix, ArizonaAges 18–60 - NCT07778212Recruiting
New drug combo for aggressive lymphoma
This trial tests a new combination of drugs for people newly diagnosed with an aggressive type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The combo includes orelabrutinib plus standard chemo-immunotherapy, and may help improve outcomes for those at intermediate or high risk.
Xiamen, FujianAges 18 years+ - NCT07185373RecruitingPhase 2/Phase 3
Newly diagnosed CNS lymphoma with orelabrutinib combination therapy
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
BeijingAges 18–75 - NCT06228963RecruitingPhase 2
Orelabrutinib for H. pylori-positive gastric MALT lymphoma
This trial tests a targeted drug called orelabrutinib for people with a specific type of stomach lymphoma that is linked to an active H. pylori infection. The goal is to see if the drug can help shrink or control the lymphoma.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05933967RecruitingPhase 2
Orelabrutinib with R-CHOP for newly diagnosed lymphoma
This Phase 2 trial tests whether adding orelabrutinib to standard chemotherapy (R-CHOP) can improve treatment for people with newly diagnosed double-expressing diffuse large B-cell lymphoma. It’s intended for adults who are well enough to receive treatment and whose lymphoma is in the body (not in the brain/spinal fluid).
Nanchang, JiangxiAges 18–70 - NCT04961515RecruitingPhase 2
Orelabrutinib with immunotherapy and temozolomide for CNS lymphoma
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
Hangzhou, ZhejiangAges 18–75 - NCT06503276RecruitingPhase 2
Orelabrutinib and radiation for a type of eye lymphoma
This trial tests a combination of a targeted drug (Orelabrutinib) and radiation therapy for adults newly diagnosed with a slow-growing lymphoma around the eye. The goal is to see if this approach works well and is safe for people who have not had treatment before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07191431Recruiting
Study of drug combo for returning brain lymphoma
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 14–80 - NCT07410520RecruitingPhase 2
New drug combo for brain lymphoma
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
Nanjing, JiangsuAges 18 years+ - NCT05600660RecruitingPhase 2
Testing a new combo treatment for newly diagnosed brain lymphoma
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
Hanzhou, ZhejiangAges 18–75 - NCT07719556RecruitingPhase 2
Orelabrutinib with obinutuzumab and venetoclax for untreated MCL
This trial tests a new combination of three targeted drugs (orelabrutinib, obinutuzumab, and venetoclax) for people with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see if this short-course combination can effectively control the disease while being gentle on the body.
Changzhou, JiangsuAges 18 years+ - NCT05728658RecruitingPhase 1
Study of ICP-248 for relapsed or refractory B-cell cancers
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
Bengbu, AnhuiAges 18–80 - NCT06082102RecruitingPhase 3
Comparing orelabrutinib and lenalidomide with rituximab for MZL
This study tests two different drug combinations for people with marginal zone lymphoma that has come back or stopped responding to previous treatment. One group gets orelabrutinib plus rituximab, and the other gets lenalidomide plus rituximab, to see which works better and has fewer side effects.
Bengbu, AuhuiAges 18 years+ - NCT06378138RecruitingPhase 2/Phase 3
Testing a new drug combo for untreated CLL or SLL
This trial tests two new oral medications (ICP-248 and Orelabrutinib) together as a first treatment for people with CLL or SLL. The goal is to see if this combination works better than current options and is safe for newly diagnosed patients.
Bengbu, AnhuiAges 18–80 - NCT06454968RecruitingPhase 2
Combination therapy for first-line marginal zone lymphoma
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06478472Recruiting
Orelabrutinib plus rituximab for marginal zone lymphoma
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
Xiamen, FujianAges 18 years+
What Orelabrutinib is being studied for
Conditions with recruiting Orelabrutinib studies.
Common questions
- Are there clinical trials studying Orelabrutinib?
- Yes. Clin2 currently lists 51 recruiting studies that include Orelabrutinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Orelabrutinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Orelabrutinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Orelabrutinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.